Background Abnormalities of coagulation and fibrinolysis are frequently observed in cancer
patients. Emerging data suggested that plasma D-dimer and fibrinogen levels correlated …

Background Cancer is a well‐known risk factor for venous thromboembolism (VTE). A
combined strategy of D‐dimer testing and clinical pre‐test probability is usually used to …

Precision oncology aims to tailor clinical decisions specifically to patients with the objective
of improving treatment outcomes. This can be achieved by leveraging omics information for …

Malignant disease is characterized by a hemostatic imbalance, usually shifted towards a
procoagulant direction, and a high incidence of thrombotic complications. The mechanisms …

D‑dimer is a widely used biomarker for indicating the activation of coagulation and
fibrinolysis, and is reported to serve important roles in cancer progression. The aim of the …

The clinical significance of COL5A2 in patients with bladder... : Medicine The clinical significance
of COL5A2 in patients with bladder cancer: A retrospective analysis of bladder cancer gene …

The last half century of cancer research has seen an explosion in our understanding of the
complex interplay between cancer cells and host-derived factors critical for cancer …

Research has established a direct link between the plasma level of D-dimer and underlying
malignancy. D-dimer has a strong association with the detection and prognosis of several …

Background Patients with cancer are commonly characterized by abnormalities in laboratory
coagulation tests, underlying a subclinical hypercoagulable condition. Due to the …

Background: Growing evidence showed that high pretreatment plasma fibrinogen could be
used as a potential prognostic marker in colorectal cancer (CRC). However, the conclusions …